On January 18, 2022, the Pan-Canadian Formulary Advisory Panel will be presenting an information session with their recommendations for the development of a framework for a potential pan-Canadian prescription drug list, or formulary.
The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health (CADTH) at the request of Health Canada. The information session will focus on the principles for developing a pan-Canadian formulary framework, a sample list of prescribed drugs to include on the potential formulary as a test case, and criteria and processes for expanding the sample list. Registration is free.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency announces consultation on streamlined review process and new reconsideration/resubmission procedures
On January 29, 2026, Canada’s Drug Agency (CDA) published Improvements to the Drug Reimbursement Review Process, which includes a section for consultation on proposed changes to the reimbursement re...Read More -
PMPRB consults on proposed Practice Directions for PMPRB hearings
The Patented Medicine Prices Review Board (PMPRB) holds public hearings in two types of matters: to determine whether the price of a medicine is excessive; and to determine whether a rights holder ha...Read More -
Canada announces new Pharmaceutical and Life Sciences Sector Task Force
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and ...Read More
